This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9 billion

( April 6, 2026, 13:31 GMT | Official Statement) -- MLex Summary: Neurocrine Biosciences has agreed to acquire Soleno Therapeutics in an all-cash transaction at $53 per share, representing a total approximate value of $2.9 billion, the companies announced. The deal, which adds Soleno’s first-in-class hyperphagia therapy to Neurocrine, “will expand Neurocrine’s portfolio of innovative medicines and strengthen its leadership position in endocrinology and rare disease,” the release said. The transaction is expected to close within 90 days of its announcement.See full release below....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login